Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into an accelerated second phase of its collaboration with a large pharmaceutical company to tailor its high-throughput pharmacokinetic (HTPK) simulation functionality within ADMET Predictor® to support the sponsor partner’s lead selection activities for small molecule programs.
“The feedback received from our partner on the first phase of customization work has been overwhelmingly positive, and they have identified several additional enhancements which will solidify our HTPK Simulation technology as a key component aligning research teams in discovery with early development,” said Dr. David Miller, vice president of ADMET Cheminformatics at Simulations Plus. “These improvements, coupled with other software engineering advances implemented in the recent APX release, will make it possible for exposure predictions and optimal dose estimates to factor into compound prioritization decisions at the discovery stage.”
“Our unique ability to collaborate 1-on-1 with companies is the definition of a win-win-win outcome,” added John DiBella, Lancaster division president for Simulations Plus. “For our sponsoring partner, they are able to design new functionality and workflows tailored to their specification within a commercially supported and validated platform. For Simulations Plus, we can leverage funding, external scientific expertise, and, most importantly, novel data to drive advances in modeling and simulation science. Finally, our entire user community can access these new capabilities to accelerate research timelines and develop better medicines more efficiently for the patients we all serve. We welcome and invite future collaborations across our entire suite of software programs.”